Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer.

Ricco N, Flor A, Wolfgeher D, Efimova EV, Ramamurthy A, Appelbe OK, Brinkman J, Truman AW, Spiotto MT, Kron SJ.

Mol Oncol. 2019 Sep;13(9):1927-1943. doi: 10.1002/1878-0261.12535. Epub 2019 Jul 26.

2.

Corrigendum to "Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall survival: A National Cancer Database Analysis" [Lung Cancer, Volume 130 (April) (2019) 162-168].

Foster CC, Rusthoven CG, Sher DJ, Feldman L, Pasquinelli M, Spiotto MT, Koshy M.

Lung Cancer. 2019 Jun;132:159. doi: 10.1016/j.lungcan.2019.04.011. Epub 2019 Apr 26. No abstract available.

PMID:
31031052
3.

Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy.

Lu K, He C, Guo N, Chan C, Ni K, Lan G, Tang H, Pelizzari C, Fu YX, Spiotto MT, Weichselbaum RR, Lin W.

Nat Biomed Eng. 2018 Aug;2(8):600-610. doi: 10.1038/s41551-018-0203-4. Epub 2018 Mar 26.

PMID:
31015630
4.

Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis.

Foster CC, Rusthoven CG, Sher DJ, Feldman L, Pasquinelli M, Spiotto MT, Koshy M.

Lung Cancer. 2019 Apr;130:162-168. doi: 10.1016/j.lungcan.2019.02.023. Epub 2019 Feb 21. Erratum in: Lung Cancer. 2019 Jun;132:159.

PMID:
30885339
5.

Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.

Foster CC, Sher DJ, Rusthoven CG, Verma V, Spiotto MT, Weichselbaum RR, Koshy M.

Radiat Oncol. 2019 Jan 28;14(1):18. doi: 10.1186/s13014-019-1222-3.

6.

Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer.

Huang L, David O, Cabay RJ, Valyi-Nagy K, Macias V, Zhong R, Wenig B, Feldman L, Weichselbaum R, Spiotto MT.

Clin Cancer Res. 2019 Mar 15;25(6):1795-1808. doi: 10.1158/1078-0432.CCR-18-1884. Epub 2018 Dec 20.

PMID:
30573692
7.

Survival outcomes for postoperative chemoradiation in intermediate-risk oral tongue cancers.

Spiotto MT, Jefferson GD, Wenig B, Markiewicz MR, Weichselbaum RR, Koshy M.

Head Neck. 2017 Dec;39(12):2537-2548. doi: 10.1002/hed.24932. Epub 2017 Sep 27.

PMID:
28960621
8.

Association between hospital volume and receipt of treatment and survival in patients with glioblastoma.

Koshy M, Sher DJ, Spiotto M, Husain Z, Engelhard H, Slavin K, Nicholas MK, Weichselbaum RR, Rusthoven C.

J Neurooncol. 2017 Dec;135(3):529-534. doi: 10.1007/s11060-017-2598-2. Epub 2017 Aug 23.

PMID:
28836140
9.

Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.

Koshy M, Malik R, Spiotto M, Mahmood U, Rusthoven CG, Sher DJ.

Lung Cancer. 2017 Jun;108:222-227. doi: 10.1016/j.lungcan.2017.04.006. Epub 2017 Apr 17.

PMID:
28625640
10.

Impact of fraction size on locally advanced oropharyngeal and nasopharyngeal cancers treated with chemoradiation.

Spiotto MT, Koshy M.

Oral Oncol. 2017 May;68:27-35. doi: 10.1016/j.oraloncology.2017.03.002. Epub 2017 Mar 17.

PMID:
28438289
11.

Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer: A National Cancer Database Analysis.

Spiotto MT, Jefferson G, Wenig B, Markiewicz M, Weichselbaum RR, Koshy M.

JAMA Otolaryngol Head Neck Surg. 2017 Jul 1;143(7):691-699. doi: 10.1001/jamaoto.2017.0012.

12.

The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications.

Spiotto M, Fu YX, Weichselbaum RR.

Sci Immunol. 2016 Sep;1(3). pii: EAAG1266. doi: 10.1126/sciimmunol.aag1266. Epub 2016 Sep 30.

13.

Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer.

Melotek JM, Cooper BT, Koshy M, Silverman JS, Spiotto MT.

J Otolaryngol Head Neck Surg. 2016 Nov 24;45(1):62.

14.

Return of induction chemotherapy in head and neck squamous cell cancers: is this time different?

Spiotto MT.

Lancet Oncol. 2016 Nov;17(11):1465-1467. doi: 10.1016/S1470-2045(16)30444-2. Epub 2016 Sep 27. No abstract available.

PMID:
27686944
15.

Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance.

Zheng W, Skowron KB, Namm JP, Burnette B, Fernandez C, Arina A, Liang H, Spiotto MT, Posner MC, Fu YX, Weichselbaum RR.

Oncotarget. 2016 Jul 12;7(28):43039-43051. doi: 10.18632/oncotarget.9915.

16.

A High-Throughput Cell-Based Screen Identified a 2-[(E)-2-Phenylvinyl]-8-Quinolinol Core Structure That Activates p53.

Bechill J, Zhong R, Zhang C, Solomaha E, Spiotto MT.

PLoS One. 2016 Apr 28;11(4):e0154125. doi: 10.1371/journal.pone.0154125. eCollection 2016.

17.

Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.

Villaflor VM, Melotek JM, Karrison TG, Brisson RJ, Blair EA, Portugal L, De Souza JA, Ginat DT, Stenson KM, Langerman A, Kocherginsky M, Spiotto MT, Hannigan N, Seiwert TY, Cohen EE, Vokes EE, Haraf DJ.

Ann Oncol. 2016 May;27(5):908-13. doi: 10.1093/annonc/mdw051. Epub 2016 Feb 15.

PMID:
26884588
18.

Hospitalizations of more than 5 days predict for worse outcomes after radiotherapy for head and neck cancer.

Spiotto MT, Koshy M.

J Community Support Oncol. 2015 Oct;13(10):367-73. doi: 10.12788/jcso.0175.

PMID:
26862912
19.

Loss of E2F1 Extends Survival and Accelerates Oral Tumor Growth in HPV-Positive Mice.

Zhong R, Bechill J, Spiotto MT.

Cancers (Basel). 2015 Dec 8;7(4):2372-85. doi: 10.3390/cancers7040895.

20.

Strategies to Overcome Late Complications from Radiotherapy for Childhood Head and Neck Cancers.

Spiotto MT, Connell PP.

Oral Maxillofac Surg Clin North Am. 2016 Feb;28(1):115-26. doi: 10.1016/j.coms.2015.07.009. Review.

PMID:
26614704
21.

Predictors and outcomes for chronic tracheostomy after chemoradiation for advanced laryngohypopharyngeal cancer.

Jefferson GD, Wenig BL, Spiotto MT.

Laryngoscope. 2016 Feb;126(2):385-91. doi: 10.1002/lary.25585. Epub 2015 Sep 7.

PMID:
26344401
22.

Notch1 Activation or Loss Promotes HPV-Induced Oral Tumorigenesis.

Zhong R, Bao R, Faber PW, Bindokas VP, Bechill J, Lingen MW, Spiotto MT.

Cancer Res. 2015 Sep 15;75(18):3958-3969. doi: 10.1158/0008-5472.CAN-15-0199. Epub 2015 Aug 20.

23.

Angiotensin-converting enzyme inhibitors predict acute kidney injury during chemoradiation for head and neck cancer.

Spiotto MT, Cao H, Mell L, Toback FG.

Anticancer Drugs. 2015 Mar;26(3):343-9. doi: 10.1097/CAD.0000000000000191.

24.

Disparities in treatment of patients with inoperable stage I non-small cell lung cancer: a population-based analysis.

Koshy M, Malik R, Spiotto M, Mahmood U, Weichselbaum R, Sher D.

J Thorac Oncol. 2015 Feb;10(2):264-71. doi: 10.1097/JTO.0000000000000418.

25.

The effect of radiotherapy dose on survival in stage III non-small-cell lung cancer patients undergoing definitive chemoradiotherapy.

Koshy M, Malik R, Sher DJ, Spiotto M, Mahmood U, Aydogan B, Weichselbaum RR.

Clin Lung Cancer. 2014 Sep;15(5):365-71. doi: 10.1016/j.cllc.2014.05.004. Epub 2014 Jun 2.

PMID:
24984565
27.

Bioluminescent imaging of HPV-positive oral tumor growth and its response to image-guided radiotherapy.

Zhong R, Pytynia M, Pelizzari C, Spiotto M.

Cancer Res. 2014 Apr 1;74(7):2073-81. doi: 10.1158/0008-5472.CAN-13-2993. Epub 2014 Feb 13.

28.

Animal models to study the mutational landscape for oral cavity and oropharyngeal cancers.

Spiotto MT, Pytynia M, Liu GF, Ranck MC, Widau R.

J Oral Maxillofac Res. 2013 Apr 1;4(1):e1. doi: 10.5037/jomr.2013.4101. Review.

29.

Effect of postradiotherapy neck dissection on nonregional disease sites.

Ranck MC, Abundo R, Jefferson G, Kolokythas A, Wenig BL, Weichselbaum RR, Spiotto MT.

JAMA Otolaryngol Head Neck Surg. 2014 Jan;140(1):12-21. doi: 10.1001/jamaoto.2013.5754.

30.

Race and competing mortality in advanced head and neck cancer.

Zakeri K, MacEwan I, Vazirnia A, Cohen EE, Spiotto MT, Haraf DJ, Vokes EE, Weichselbaum RR, Mell LK.

Oral Oncol. 2014 Jan;50(1):40-4. doi: 10.1016/j.oraloncology.2013.09.012. Epub 2013 Oct 14.

31.

Racial parities in outcomes after radiotherapy for head and neck cancer.

Liu GF, Ranck MC, Solanki AA, Cao H, Kolokythas A, Wenig BL, Chen L, Ard S, Weichselbaum RR, Halpern H, Spiotto MT.

Cancer. 2014 Jan 15;120(2):244-52. doi: 10.1002/cncr.28417. Epub 2013 Oct 10.

32.

Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer.

Herman LC, Chen L, Garnett A, Feldman LE, Smith B, Weichselbaum RR, Spiotto MT.

Oral Oncol. 2014 Jan;50(1):52-8. doi: 10.1016/j.oraloncology.2013.08.007. Epub 2013 Sep 19.

PMID:
24055193
33.

Lymph node density--prognostic value in head and neck cancer.

Rudra S, Spiotto MT, Witt ME, Blair EA, Stenson K, Haraf DJ.

Head Neck. 2014 Feb;36(2):266-72. doi: 10.1002/hed.23299. Epub 2013 Jun 14.

PMID:
23765406
34.

Spleen cells from young but not old immunized mice eradicate large established cancers.

Schreiber K, Arina A, Engels B, Spiotto MT, Sidney J, Sette A, Karrison TG, Weichselbaum RR, Rowley DA, Schreiber H.

Clin Cancer Res. 2012 May 1;18(9):2526-33. doi: 10.1158/1078-0432.CCR-12-0127. Epub 2012 Mar 13.

35.

Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth.

Spiotto MT, Banh A, Papandreou I, Cao H, Galvez MG, Gurtner GC, Denko NC, Le QT, Koong AC.

Cancer Res. 2010 Jan 1;70(1):78-88. doi: 10.1158/0008-5472.CAN-09-2747. Epub 2009 Dec 22.

36.

Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways.

Fels DR, Ye J, Segan AT, Kridel SJ, Spiotto M, Olson M, Koong AC, Koumenis C.

Cancer Res. 2008 Nov 15;68(22):9323-30. doi: 10.1158/0008-5472.CAN-08-2873.

37.

Obesity and risk of biochemical failure for patients receiving salvage radiotherapy after prostatectomy.

King CR, Spiotto MT, Kapp DS.

Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1017-22. doi: 10.1016/j.ijrobp.2008.05.041. Epub 2008 Aug 15.

PMID:
18707829
38.

Improved outcomes with higher doses for salvage radiotherapy after prostatectomy.

King CR, Spiotto MT.

Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):23-7. doi: 10.1016/j.ijrobp.2007.09.047. Epub 2008 Jan 22.

PMID:
18207668
39.

Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.

King CR, Presti JC, Brooks JD, Gill H, Spiotto MT.

Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1472-7. Epub 2007 Nov 1.

PMID:
17935902
40.

Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients.

Spiotto MT, Hancock SL, King CR.

Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):54-61. Epub 2007 Apr 24.

PMID:
17459606
41.

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.

Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, Yu P, Fu YX, Weichselbaum RR, Rowley DA, Kranz DM, Schreiber H.

J Exp Med. 2007 Jan 22;204(1):49-55. Epub 2007 Jan 8.

42.
44.

Bystander elimination of antigen loss variants in established tumors.

Spiotto MT, Rowley DA, Schreiber H.

Nat Med. 2004 Mar;10(3):294-8. Epub 2004 Feb 22.

PMID:
14981514
45.

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.

Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF.

Cancer Res. 2004 Feb 1;64(3):1140-5.

46.

Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation.

Spiotto MT, Fu YX, Schreiber H.

Curr Opin Immunol. 2003 Dec;15(6):725-30. Review.

PMID:
14630209
47.

Genetic changes occurring in established tumors rapidly stimulate new antibody responses.

Spiotto MT, Reth MA, Schreiber H.

Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5425-30. Epub 2003 Apr 17.

48.

Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells.

Yu P, Spiotto MT, Lee Y, Schreiber H, Fu YX.

J Exp Med. 2003 Apr 21;197(8):985-95. Epub 2003 Apr 14.

49.

Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells.

Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, Fu YX, Schreiber H.

Immunity. 2002 Dec;17(6):737-47.

50.

STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells .

Spiotto MT, Chung TD.

Prostate. 2000 Feb 15;42(3):186-95.

PMID:
10639189

Supplemental Content

Loading ...
Support Center